IL17A and rheumatoid arthritis: After 6 months of treatment, there were no differences in the numbers of CD4+IL-17A+T-lymphocytes between nonresponder and responder RA patients, but the numbers of CD4+IL-17A+TN remained significantly increased in nonresponders.